

Income statement

Three months ended 30th June 2009

	Results before major restructuring £m	Major restructuring £m	Total £m	Results before major restructuring \$m	Major restructuring \$m	Total \$m
TURNOVER	6,747	-	6,747	10,527	-	10,527
Cost of sales	(1,621)	(71)	(1,692)	(2,531)	(115)	(2,646)
Gross profit	5,126	(71)	5,055	7,996	(115)	7,881
Selling, general and administration	(2,227)	(65)	(2,292)	(3,468)	(102)	(3,570)
Research and development	(923)	(50)	(973)	(1,449)	(78)	(1,527)
Other operating income	405	-	405	611	-	611
OPERATING PROFIT	2,381	(186)	2,195	3,690	(295)	3,395
Finance income	18	-	18	29	-	29
Finance expense	(166)	(2)	(168)	(261)	(4)	(265)
Profit on disposal of interest in associate	-	-	-	7	-	7
Share of after tax profits of associates and joint ventures	17	-	17	27	-	27
PROFIT BEFORE TAXATION	2,250	(188)	2,062	3,492	(299)	3,193
Taxation	(652)	51	(601)	(1,011)	80	(931)
PROFIT AFTER TAXATION FOR THE PERIOD	1,598	(137)	1,461	2,481	(219)	2,262
Profit attributable to minority interests	26	-	26	42	-	42
Profit attributable to shareholders	1,572	(137)	1,435	2,439	(219)	2,220
	1,598	(137)	1,461	2,481	(219)	2,262
EARNINGS PER SHARE	31.0p		28.3p	48.4¢	-	44.1¢
Diluted earnings per share	30.8p		28.1p	48.0¢	-	43.8¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

Income statement

Six months ended 30th June 2009

	Results before major restructuring £m	Major restructuring £m	Total £m	Results before major restructuring \$m	Major restructuring \$m	Total \$m
TURNOVER	13,516	-	13,516	20,274	-	20,274
Cost of sales	(3,265)	(214)	(3,479)	(4,898)	(321)	(5,219)
Gross profit	10,251	(214)	10,037	15,376	(321)	15,055
Selling, general and administration	(4,356)	(136)	(4,492)	(6,534)	(204)	(6,738)
Research and development	(1,997)	(100)	(2,097)	(2,996)	(150)	(3,146)
Other operating income	459	-	459	689	-	689
	4,357	(450)	3,907	6,535	(675)	5,860
OPERATING PROFIT						
Finance income	46	-	46	69	-	69
Finance expense	(368)	(3)	(371)	(552)	(5)	(557)
Profit on disposal of interest in associate	115	-	115	173	-	173
Share of after tax profits of associates and joint ventures	31	-	31	47	-	47
	4,181	(453)	3,728	6,272	(680)	5,592
PROFIT BEFORE TAXATION						
Taxation	(1,212)	114	(1,098)	(1,818)	171	(1,647)
	2,969	(339)	2,630	4,454	(509)	3,945
PROFIT AFTER TAXATION FOR THE PERIOD						
Profit attributable to minority interests	64	-	64	96	-	96
Profit attributable to shareholders	2,905	(339)	2,566	4,358	(509)	3,849
	2,969	(339)	2,630	4,454	(509)	3,945
EARNINGS PER SHARE	57.3p		50.6p	86.0¢		75.9¢
Diluted earnings per share	56.9p		50.3p	85.4¢		75.5¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

Turnover

Pharmaceuticals

Three months ended 30th June 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
Respiratory	1,734	825	550	359	2,706	1,289	858	559
<i>Avamys/Veramyst</i>	47	18	16	13	72	28	24	20
<i>Flixonase/Flonase</i>	39	8	12	19	63	13	19	31
<i>Flixotide/Flovent</i>	189	97	43	49	295	151	67	77
<i>Seretide/Advair</i>	1,245	648	401	196	1,941	1,011	626	304
<i>Serevent</i>	59	18	29	12	93	29	45	19
<i>Ventolin</i>	112	32	36	44	175	50	56	69
<i>Zyrtec</i>	17	-	-	17	27	-	-	27
Anti-virals	952	496	236	220	1,495	773	375	347
HIV	382	164	156	62	599	257	245	97
<i>Agenerase, Lexiva</i>	43	23	16	4	68	36	26	6
<i>Combivir</i>	102	44	37	21	160	69	58	33
<i>Epivir</i>	31	11	12	8	49	17	19	13
<i>Epzicom/Kivexa</i>	129	50	59	20	202	78	92	32
<i>Trizivir</i>	48	25	20	3	75	39	31	5
<i>Ziagen</i>	25	11	9	5	39	17	14	8
<i>Valtrex</i>	379	291	39	49	590	452	62	76
<i>Relenza</i>	60	19	25	16	103	29	44	30
<i>Zeffix</i>	55	5	8	42	86	7	13	66
Central nervous system	449	142	144	163	703	226	224	253
<i>Imigran/Imitrex</i>	68	33	23	12	106	51	36	19
<i>Lamictal</i>	103	45	38	20	164	72	60	32
<i>Requip</i>	51	6	35	10	80	9	55	16
<i>Requip XL</i>	30	8	22	-	46	12	34	-
<i>Seroxat/Paxil</i>	138	13	27	98	215	20	43	152
<i>Treximet</i>	12	12	-	-	19	19	-	-
<i>Wellbutrin/Wellbutrin XL</i>	30	20	7	3	49	33	11	5
Cardiovascular and urogenital	580	360	145	75	903	561	226	116
<i>Arixtra</i>	61	33	23	5	95	52	35	8
<i>Avodart</i>	134	83	37	14	208	129	57	22
<i>Coreg, Coreg CR</i>	51	50	-	1	80	78	-	2
<i>Fraxiparine</i>	58	-	43	15	91	-	67	24
<i>Levitra</i>	18	17	1	-	28	27	1	-
<i>Lovaza</i>	104	104	-	-	162	162	-	-
<i>Vesicare</i>	26	26	-	-	40	40	-	-
<i>Volibris</i>	4	-	4	-	6	-	6	-
Metabolic	303	149	71	83	473	233	111	129
<i>Avandia products</i>	198	107	46	45	309	167	72	70
<i>Avandia</i>	121	71	18	32	189	111	28	50
<i>Avandamet</i>	67	29	26	12	105	45	41	19
<i>Bonviva/Boniva</i>	66	41	23	2	103	63	36	4
Anti-bacterials	381	46	146	189	596	71	230	295
<i>Augmentin</i>	146	11	61	74	230	17	97	116
Oncology and emesis	166	88	50	28	258	136	78	44
<i>Hycamtin</i>	43	24	15	4	67	38	23	6
<i>Promacta</i>	3	3	-	-	5	5	-	-
<i>Tyverb/Tykerb</i>	41	17	18	6	64	26	29	9
<i>Zofran</i>	30	4	14	12	47	6	22	19
Vaccines	756	196	320	240	1,172	302	497	373
<i>Boostrix</i>	39	21	10	8	61	32	16	13
<i>Cervarix</i>	73	-	63	10	113	-	97	16
<i>Fluarix, FluLaval</i>	14	3	-	11	21	4	-	17
<i>Flu Pre-Pandemic</i>	30	25	5	-	45	37	8	-
<i>Hepatitis</i>	195	87	72	36	301	133	112	56
<i>Infanrix, Pediarix</i>	154	38	91	25	242	60	143	39
<i>Rotarix</i>	71	22	12	37	110	34	19	57
<i>Synflorix</i>	12	-	10	2	18	-	15	3
Other	261	2	84	175	405	3	130	272
	5,582	2,304	1,746	1,532	8,711	3,594	2,729	2,388

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

Turnover

Pharmaceuticals

Six months ended 30th June 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
Respiratory	3,469	1,669	1,096	704	5,204	2,504	1,644	1,056
<i>Avamys/Veramyst</i>	78	38	25	15	117	57	37	23
<i>Flixonase/Flonase</i>	108	18	24	66	162	27	36	99
<i>Flixotide/Flovent</i>	384	196	91	97	576	294	136	146
<i>Seretide/Advair</i>	2,459	1,301	795	363	3,689	1,951	1,193	545
<i>Serevent</i>	121	37	60	24	182	56	90	36
<i>Ventolin</i>	228	70	73	85	342	105	109	128
<i>Zyrtec</i>	35	-	-	35	53	-	-	53
Anti-virals	2,068	984	576	508	3,102	1,476	864	762
HIV	801	359	325	117	1,202	538	488	176
<i>Agenerase, Lexiva</i>	91	50	33	8	137	75	50	12
<i>Combivir</i>	214	97	78	39	321	145	117	59
<i>Epivir</i>	65	24	26	15	98	36	39	23
<i>Epzicom/Kivexa</i>	266	108	121	37	399	162	181	56
<i>Trizivir</i>	104	55	44	5	156	82	66	8
<i>Ziagen</i>	52	25	18	9	78	37	27	14
<i>Valtrex</i>	723	548	81	94	1,085	822	122	141
<i>Relenza</i>	282	30	135	117	423	45	202	176
<i>Zeffix</i>	108	9	15	84	162	13	23	126
Central nervous system	948	358	289	301	1,422	537	433	452
<i>Imigran/Imitrex</i>	132	61	48	23	198	91	72	35
<i>Lamictal</i>	247	131	77	39	371	196	116	59
<i>Requip</i>	101	14	67	20	152	21	101	30
<i>Requip XL</i>	52	13	39	-	78	19	59	-
<i>Seroxat/Paxil</i>	264	27	55	182	396	40	83	273
<i>Treximet</i>	26	26	-	-	39	39	-	-
<i>Wellbutrin/Wellbutrin XL</i>	94	74	13	7	141	111	19	11
Cardiovascular and urogenital	1,131	704	286	141	1,696	1,056	429	211
<i>Arixtra</i>	120	66	45	9	180	99	67	14
<i>Avodart</i>	256	156	73	27	384	234	109	41
<i>Coreg, Coreg CR</i>	102	101	-	1	153	151	-	2
<i>Fraxiparine</i>	113	-	86	27	170	-	129	41
<i>Levitra</i>	38	36	2	-	57	54	3	-
<i>Lovaza</i>	210	209	-	1	315	313	-	2
<i>Vesicare</i>	50	50	-	-	75	75	-	-
<i>Volibris</i>	6	-	6	-	9	-	9	-
Metabolic	597	299	139	159	896	449	209	238
<i>Avandia products</i>	395	219	89	87	593	328	134	131
<i>Avandia</i>	242	145	36	61	363	217	54	92
<i>Avandamet</i>	133	60	50	23	200	90	75	35
<i>Bonviva/Boniva</i>	128	79	44	5	192	118	66	8
Anti-bacterials	807	93	335	379	1,210	139	503	568
<i>Augmentin</i>	332	27	145	160	498	40	218	240
Oncology and emesis	310	158	101	51	465	237	151	77
<i>Hycamtin</i>	86	50	30	6	129	75	45	9
<i>Promacta</i>	5	5	-	-	8	8	-	-
<i>Tyverb/Tykerb</i>	75	28	35	12	113	42	53	18
<i>Zofran</i>	62	11	28	23	93	16	42	35
Vaccines	1,381	315	606	460	2,072	473	909	690
<i>Boostrix</i>	65	32	18	15	98	48	27	23
<i>Cervarix</i>	121	-	102	19	182	-	153	29
<i>Fluarix, FluLaval</i>	20	3	-	17	30	4	-	26
<i>Flu Pre-Pandemic</i>	36	25	10	1	54	37	15	2
<i>Hepatitis</i>	344	139	133	72	516	208	200	108
<i>Infanrix, Pediarix</i>	329	77	200	52	494	116	300	78
<i>Rotarix</i>	128	37	25	66	192	55	38	99
<i>Synflorix</i>	12	-	10	2	18	-	15	3
Other	494	7	158	329	741	10	237	494
	11,205	4,587	3,586	3,032	16,808	6,881	5,379	4,548

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

Turnover

Consumer Healthcare Three months ended 30th June 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
Over-the-counter medicines	573	183	185	205	894	286	286	322
<i>alli</i>	82	25	56	1	125	39	84	2
<i>Breathe Right</i>	20	10	5	5	32	16	8	8
Cold sore franchise	20	9	8	3	32	14	13	5
<i>Nicotene</i> replacement therapy	88	68	15	5	137	105	24	8
<i>Panadol</i>	94	-	20	74	147	-	31	116
<i>Tums</i>	25	22	-	3	40	35	-	5
Oral healthcare	366	71	190	105	571	111	296	164
<i>Aquafresh franchise</i>	121	21	71	29	190	33	111	46
<i>Biotene</i>	6	5	1	-	9	8	1	-
Dental care	84	20	32	32	131	31	50	50
<i>Sensodyne franchise</i>	113	23	50	40	177	37	77	63
Nutritional healthcare	226	-	130	96	352	-	201	151
<i>Horlicks</i>	61	-	4	57	96	-	6	90
<i>Lucozade</i>	106	-	92	14	164	-	142	22
<i>Ribena</i>	44	-	33	11	68	-	51	17
	1,165	254	505	406	1,817	397	783	637

Turnover

Consumer Healthcare Six months ended 30th June 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
Over-the counter-medicines	1,140	363	341	436	1,710	545	511	654
<i>alli</i>	114	54	59	1	171	81	88	2
<i>Breathe Right</i>	47	24	12	11	71	36	18	17
Cold sore franchise	43	18	19	6	65	27	29	9
<i>Nicotene</i> replacement therapy	170	126	32	12	255	189	48	18
<i>Panadol</i>	193	-	40	153	290	-	60	230
<i>Tums</i>	55	49	-	6	83	74	-	9
Oral healthcare	734	149	374	211	1,101	223	561	317
<i>Aquafresh franchise</i>	249	48	144	57	374	72	216	86
<i>Biotene</i>	12	10	1	1	18	15	1	2
Dental care	164	39	60	65	246	58	90	98
<i>Sensodyne franchise</i>	225	49	97	79	338	74	145	119
Nutritional healthcare	437	-	225	212	656	-	338	318
<i>Horlicks</i>	136	-	9	127	204	-	13	191
<i>Lucozade</i>	186	-	157	29	279	-	235	44
<i>Ribena</i>	82	-	58	24	123	-	87	36
	2,311	512	940	859	3,467	768	1,410	1,289

Balance sheet

	30th June 2009 £m	30th June 2009 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	8,875	14,644
Goodwill	2,015	3,325
Other intangible assets	5,787	9,549
Investments in associates and joint ventures	448	739
Other investments	463	764
Deferred tax assets	2,570	4,240
Derivative financial instruments	61	101
Other non-current assets	493	813
Total non-current assets	20,712	34,175
Current assets		
Inventories	3,910	6,451
Current tax recoverable	55	91
Trade and other receivables	5,363	8,849
Derivative financial instruments	283	467
Liquid investments	290	479
Cash and cash equivalents	5,346	8,821
Assets held for sale	2	3
Total current assets	15,249	25,161
TOTAL ASSETS	35,961	59,336
LIABILITIES		
Current liabilities		
Short-term borrowings	(1,185)	(1,955)
Trade and other payables	(5,161)	(8,516)
Derivative financial instruments	(400)	(660)
Current tax payable	(875)	(1,444)
Short-term provisions	(1,413)	(2,331)
Total current liabilities	(9,034)	(14,906)
Non-current liabilities		
Long-term borrowings	(13,067)	(21,561)
Deferred tax liabilities	(497)	(820)
Pensions and other post-employment benefits	(3,664)	(6,046)
Other provisions	(1,276)	(2,105)
Other non-current liabilities	(392)	(647)
Total non-current liabilities	(18,896)	(31,179)
TOTAL LIABILITIES	(27,930)	(46,085)
NET ASSETS	8,031	13,251
EQUITY		
Share capital	1,416	2,336
Share premium account	1,341	2,213
Retained earnings	4,257	7,024
Other reserves	703	1,160
Shareholders' equity	7,717	12,733
Minority interests	314	518
TOTAL EQUITY	8,031	13,251

US dollar amounts shown above are a convenience transaction of the sterling amounts using the period end rate of £1/\$1.65.